Physician profile
David Mark Weitzman
NPI 1376776781
$1,180.68
in general payments reported to CMS, 2019-2025
15 companies · $167 in 2025
The $167 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $14.09 · 2021: $292 · 2022: $53.60 · 2023: $421 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $588.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $196.36 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Janssen Pharmaceuticals, INC | $166.85 | 2025 | Spravato |
| Novo Nordisk INC | $137.36 | 2021-2023 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $122.67 | 2023 | Epclusa |
| Lilly USA, LLC | $113.69 | 2019 | |
| Indivior INC. | $103.13 | 2019 | |
| Boston Scientific Corporation | $99.08 | 2021-2023 | Varithena Administration Pack |
| Merz North America, INC. | $83.43 | 2021 | |
| Medtronic, INC. | $54.09 | 2023 | Intellis Adaptivestim |
| Takeda Pharmaceuticals U.S.A., INC. | $43.48 | 2022-2023 | Trintellix |
| Leo Pharma INC. | $30.43 | 2022 | |
| Amgen INC. | $16.02 | 2019 | |
| Masimo Corporation | $14.09 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Weitzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.